Paul A. Goepfert

Infectious Disease

908 20th St S
Birmingham, AL 35205

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 157 publications

mRNA delivery of a class 1/4 SARS-CoV-2 neutralizing antibody protects against diverse sarbecoviruses in a lethal mouse challenge model.

mRNA delivery of a class 1/4 SARS-CoV-2 neutralizing antibody protects against diverse sarbecoviruses in a lethal mouse challenge model.

Journal: Proceedings of the National Academy of Sciences of the United States of America

Published: June 08, 2026

A phase 1 randomized controlled trial to evaluate the safety and immunogenicity of a HIV monomeric gp120 protein B-cell lineage targeting HIV vaccine in healthy adults.

A phase 1 randomized controlled trial to evaluate the safety and immunogenicity of a HIV monomeric gp120 protein B-cell lineage targeting HIV vaccine in healthy adults.

Journal: medRxiv : the preprint server for health sciences

Published: June 05, 2026

Emergence of neutralizing RBD antibodies following Omicron infection with limited activity against ancestral SARS-CoV-2.

Emergence of neutralizing RBD antibodies following Omicron infection with limited activity against ancestral SARS-CoV-2.

Journal: iScience

Published: March 04, 2026

Terminally Differentiated Influenza-Specific Effector Memory B Cells Circulate after Live Attenuated Influenza Vaccination.

Terminally Differentiated Influenza-Specific Effector Memory B Cells Circulate after Live Attenuated Influenza Vaccination.

Journal: bioRxiv : the preprint server for biology

Published: February 06, 2026

IDSA 2025 Guidelines on the Use of Vaccines for the Prevention of Seasonal COVID-19, Influenza, and RSV Infections in Immunocompromised Patients.

IDSA 2025 Guidelines on the Use of Vaccines for the Prevention of Seasonal COVID-19, Influenza, and RSV Infections in Immunocompromised Patients.

Journal: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America

Published: January 23, 2026

IDSA 2025 Guideline on the Use of Vaccines for the Prevention of Seasonal Influenza Infections in Immunocompromised Patients.

IDSA 2025 Guideline on the Use of Vaccines for the Prevention of Seasonal Influenza Infections in Immunocompromised Patients.

Journal: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America

Published: January 23, 2026

AS01B-, MF59-, and alum-based adjuvants and HIV vaccine immunogenicity: a post-hoc cross-protocol comparison of results from HVTN 100, 107, 120, and 702.

AS01B-, MF59-, and alum-based adjuvants and HIV vaccine immunogenicity: a post-hoc cross-protocol comparison of results from HVTN 100, 107, 120, and 702.

Journal: Frontiers in immunology

Published: December 15, 2025

Impact of prior SARS-CoV-2 acquisition on binding and neutralizing antibody responses following COVID-19 vaccination: A cross-protocol analysis of individual-level data from six phase 3 clinical trials.

Impact of prior SARS-CoV-2 acquisition on binding and neutralizing antibody responses following COVID-19 vaccination: A cross-protocol analysis of individual-level data from six phase 3 clinical trials.

Journal: Vaccine

Published: December 11, 2025

CD151 identifies a cytotoxic CD4 T cell population enriched in people with HIV that later develop cancer.

CD151 identifies a cytotoxic CD4 T cell population enriched in people with HIV that later develop cancer.

Journal: Journal of immunology (Baltimore, Md. : 1950)

Published: November 19, 2025

The neutralizing antibody titer correlate of COVID-19 risk in the COVID-19 variant immunologic landscape (COVAIL) trial was not modified by SARS-CoV-2 amino acid sequence distances.

The neutralizing antibody titer correlate of COVID-19 risk in the COVID-19 variant immunologic landscape (COVAIL) trial was not modified by SARS-CoV-2 amino acid sequence distances.

Journal: Vaccine

Published: October 31, 2025

Association between COVID-19 vaccine efficacy and epidemic force of infection.

Association between COVID-19 vaccine efficacy and epidemic force of infection.

Journal: NPJ vaccines

Published: September 12, 2025

Vaccination with mRNA-encoded membrane-anchored HIV envelope trimers elicited tier 2 neutralizing antibodies in a phase 1 clinical trial.

Vaccination with mRNA-encoded membrane-anchored HIV envelope trimers elicited tier 2 neutralizing antibodies in a phase 1 clinical trial.

Journal: Science translational medicine

Published: July 30, 2025

Showing 1-12 of 157

Last Updated: 09/26/2026